Published in Trends Mol Med on December 13, 2005
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 3.61
Control of macrophage activation and function by PPARs. Circ Res (2010) 2.34
Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther (2007) 2.30
NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest (2008) 2.29
Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med (2009) 1.81
A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet (2011) 1.78
Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med (2011) 1.62
rBMP represses Wnt signaling and influences skeletal progenitor cell fate specification during bone repair. J Bone Miner Res (2010) 1.56
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther (2008) 1.54
Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect. Nat Med (2016) 1.46
Delphinidin, one of the major anthocyanidins, prevents bone loss through the inhibition of excessive osteoclastogenesis in osteoporosis model mice. PLoS One (2014) 1.46
Intermittent hypoxia effect on osteoclastogenesis stimulated by neuroblastoma cells. PLoS One (2014) 1.42
Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells. BMC Complement Altern Med (2017) 1.39
Topical HPMC/S-Nitrosoglutathione Solution Decreases Inflammation and Bone Resorption in Experimental Periodontal Disease in Rats. PLoS One (2016) 1.39
The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-kappaB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association. Mol Cell Biol (2008) 1.26
Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem (2010) 1.26
Interaction of staphylococci with bone. Int J Med Microbiol (2009) 1.23
The multiple faces of autoimmune-mediated bone loss. Nat Rev Endocrinol (2010) 1.22
Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer (2008) 1.19
VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J Biol Chem (2008) 1.19
A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis (2006) 1.18
The atypical PKCs in inflammation: NF-κB and beyond. Immunol Rev (2012) 1.17
RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med (2009) 1.17
Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res (2013) 1.16
Altered functional loading causes differential effects in the subchondral bone and condylar cartilage in the temporomandibular joint from young mice. Osteoarthritis Cartilage (2008) 1.15
Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. Proc Natl Acad Sci U S A (2011) 1.13
Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int (2010) 1.12
Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J Bone Miner Res (2008) 1.12
Transcriptional regulatory cascades in Runx2-dependent bone development. Tissue Eng Part B Rev (2012) 1.10
Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res (2010) 1.10
DNA-PK contributes to the phosphorylation of AIRE: importance in transcriptional activity. Biochim Biophys Acta (2007) 1.10
Tmem64 modulates calcium signaling during RANKL-mediated osteoclast differentiation. Cell Metab (2013) 1.09
Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS One (2011) 1.08
Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice. Mol Ther (2009) 1.06
Transcriptional regulation of bone and joint remodeling by NFAT. Immunol Rev (2010) 1.06
Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice. J Bone Miner Res (2008) 1.04
The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist (2011) 1.03
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw (2009) 1.03
Tenofovir-associated bone density loss. Ther Clin Risk Manag (2010) 1.02
Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.01
Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res (2013) 0.99
The molecular mechanism behind bone remodelling: a review. Clin Oral Investig (2009) 0.99
Staphylococcus aureus protein A binds to osteoblasts and triggers signals that weaken bone in osteomyelitis. PLoS One (2011) 0.98
Porphyromonas gingivalis infection-induced tissue and bone transcriptional profiles. Mol Oral Microbiol (2010) 0.96
Staphylococcus aureus induces expression of receptor activator of NF-kappaB ligand and prostaglandin E2 in infected murine osteoblasts. Infect Immun (2008) 0.96
HDAC3 and HDAC7 have opposite effects on osteoclast differentiation. J Biol Chem (2011) 0.95
RANKL, osteopontin, and osteoclast homeostasis in a hyperocclusion mouse model. Eur J Oral Sci (2008) 0.94
Protein tyrosine phosphatase epsilon regulates integrin-mediated podosome stability in osteoclasts by activating Src. Mol Biol Cell (2009) 0.94
Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. J Bone Miner Res (2009) 0.92
Delayed bone regeneration is linked to chronic inflammation in murine muscular dystrophy. J Bone Miner Res (2014) 0.92
SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion. FASEB J (2015) 0.92
Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer (2013) 0.91
Control of bone resorption in mice by Schnurri-3. Proc Natl Acad Sci U S A (2012) 0.90
Negative regulation of NF-κB and its involvement in rheumatoid arthritis. Arthritis Res Ther (2011) 0.89
Negative feedback Inhibition of NFATc1 by DYRK1A regulates bone homeostasis. J Biol Chem (2009) 0.89
Therapeutic implications of osteoprotegerin. Cancer Cell Int (2009) 0.89
Complex dynamics of osteoclast formation and death in long-term cultures. PLoS One (2008) 0.88
Absence of ERRalpha in female mice confers resistance to bone loss induced by age or estrogen-deficiency. PLoS One (2009) 0.87
Segmental bone defects: from cellular and molecular pathways to the development of novel biological treatments. J Cell Mol Med (2010) 0.87
Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy. Paediatr Drugs (2015) 0.86
Autocrine signaling is a key regulatory element during osteoclastogenesis. Biol Open (2014) 0.86
The adaptor protein p62/SQSTM1 in osteoclast signaling pathways. J Mol Signal (2012) 0.86
Osteoblast-induced osteoclast apoptosis by fas ligand/FAS pathway is required for maintenance of bone mass. Cell Death Differ (2015) 0.85
Diametrical diseases reflect evolutionary-genetic tradeoffs: Evidence from psychiatry, neurology, rheumatology, oncology and immunology. Evol Med Public Health (2015) 0.85
Increased resorptive activity and accompanying morphological alterations in osteoclasts derived from the oim/oim mouse model of osteogenesis imperfecta. J Cell Biochem (2007) 0.85
The adaptive nature of the bone-periodontal ligament-cementum complex in a ligature-induced periodontitis rat model. Biomed Res Int (2013) 0.85
Calcitonin and prednisolone display antagonistic actions on bone and have synergistic effects in experimental arthritis. Am J Pathol (2007) 0.85
Mediators of inflammation-induced bone damage in arthritis and their control by herbal products. Evid Based Complement Alternat Med (2013) 0.85
Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass. J Bone Miner Res (2013) 0.85
Emerging Functions of RANKL in Lymphoid Tissues. Front Immunol (2012) 0.85
Plasminogen/plasmin modulates bone metabolism by regulating the osteoblast and osteoclast function. J Biol Chem (2011) 0.85
Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis. Cell Res (2013) 0.85
Transgenic mice with OIP-1/hSca overexpression targeted to the osteoclast lineage develop an osteopetrosis bone phenotype. J Pathol (2007) 0.85
Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo. Exp Cell Res (2011) 0.85
Hypoxia inducible factor-1α directly induces the expression of receptor activator of nuclear factor-κB ligand in periodontal ligament fibroblasts. Mol Cells (2011) 0.84
A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth. Oncogene (2011) 0.84
Follicle-Stimulating Hormone Increases the Risk of Postmenopausal Osteoporosis by Stimulating Osteoclast Differentiation. PLoS One (2015) 0.84
Amlexanox Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss. Sci Rep (2015) 0.83
Regulation of dendritic cell survival and cytokine production by osteoprotegerin. J Leukoc Biol (2009) 0.83
Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration. Breast Cancer Res (2012) 0.83
Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone. J Biol Chem (2011) 0.83
Cell interactions in bone tissue engineering. J Cell Mol Med (2009) 0.83
Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor. J Biol Chem (2011) 0.82
Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-κB pathways. Osteoporos Int (2012) 0.82
Role of protein-tyrosine phosphatases in regulation of osteoclastic activity. Cell Mol Life Sci (2009) 0.82
Involvement of SOCS3 in regulation of CD11c+ dendritic cell-derived osteoclastogenesis and severe alveolar bone loss. Infect Immun (2009) 0.81
High-Fat-Diet-Induced Weight Gain Ameliorates Bone Loss without Exacerbating AβPP Processing and Cognition in Female APP/PS1 Mice. Front Cell Neurosci (2014) 0.81
Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. J Clin Invest (2015) 0.81
Focus on the p38 MAPK signaling pathway in bone development and maintenance. Bonekey Rep (2015) 0.81
Comparative proteomic analysis of hypertrophic chondrocytes in osteoarthritis. Clin Proteomics (2015) 0.81
Dual Effect of Chrysanthemum indicum Extract to Stimulate Osteoblast Differentiation and Inhibit Osteoclast Formation and Resorption In Vitro. Evid Based Complement Alternat Med (2014) 0.81
Molecular analysis of the vaginal response to estrogens in the ovariectomized rat and postmenopausal woman. BMC Med Genomics (2008) 0.81
Vitamin D metabolism, functions and needs: from science to health claims. Eur J Nutr (2012) 0.81
Breast cancer at bone metastatic sites: recent discoveries and treatment targets. J Cell Commun Signal (2011) 0.81
Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB. Int J Mol Sci (2015) 0.81
Diverse osteoclastogenesis of bone marrow from mandible versus long bone. J Periodontol (2013) 0.80
(+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation. PLoS One (2014) 0.80
Bone-targeting agents in prostate cancer. Cancer Metastasis Rev (2014) 0.80
Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis. BMC Cancer (2015) 0.80
Cerebral organoids model human brain development and microcephaly. Nature (2013) 9.07
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002) 5.02
Mitogen-activated protein kinases in apoptosis regulation. Oncogene (2004) 4.76
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell (2002) 4.35
The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors. Nat Immunol (2007) 4.12
Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature (2006) 4.09
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82
Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature (2002) 3.74
Osteoprotection by semaphorin 3A. Nature (2012) 3.40
Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis. Immunity (2003) 3.36
RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol (2001) 3.27
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med (2005) 3.26
The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell (2013) 3.19
AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19
Control of cell polarity and motility by the PtdIns(3,4,5)P3 phosphatase SHIP1. Nat Cell Biol (2006) 3.19
Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature (2005) 3.09
Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med (2006) 3.09
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med (2007) 2.91
Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate. Cell (2010) 2.91
The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol (2004) 2.90
The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity (2008) 2.81
Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity (2004) 2.76
Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. Cell Stem Cell (2011) 2.69
Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest (2003) 2.68
The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity (2003) 2.67
The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity (2008) 2.57
ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature (2012) 2.53
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet (2011) 2.47
Genome-wide RNAi screen identifies genes involved in intestinal pathogenic bacterial infection. Science (2009) 2.47
T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med (2006) 2.38
A genome-wide Drosophila screen for heat nociception identifies α2δ3 as an evolutionarily conserved pain gene. Cell (2010) 2.37
A global in vivo Drosophila RNAi screen identifies NOT3 as a conserved regulator of heart function. Cell (2010) 2.27
Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging. Stroke (2012) 2.18
RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci (2008) 2.10
Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med (2003) 2.04
Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int (2008) 1.99
Rank signaling links the development of invariant γδ T cell progenitors and Aire(+) medullary epithelium. Immunity (2012) 1.94
TCR affinity and negative regulation limit autoimmunity. Nat Med (2004) 1.94
Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med (2006) 1.93
Dexras1 potentiates photic and suppresses nonphotic responses of the circadian clock. Neuron (2004) 1.89
Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology (2009) 1.83
Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J Exp Med (2011) 1.79
Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes (2009) 1.78
Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res (2009) 1.78
Vav1 controls integrin clustering and MHC/peptide-specific cell adhesion to antigen-presenting cells. Immunity (2002) 1.77
Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation (2010) 1.77
High precision quantitative proteomics using iTRAQ on an LTQ Orbitrap: a new mass spectrometric method combining the benefits of all. J Proteome Res (2009) 1.75
Lineage-committed osteoclast precursors circulate in blood and settle down into bone. J Bone Miner Res (2011) 1.74
Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res (2007) 1.74
Insulin-like growth factor-1 and PTEN deletion enhance cardiac L-type Ca2+ currents via increased PI3Kalpha/PKB signaling. Circ Res (2006) 1.71
AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis. Oncogene (2004) 1.68
Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol (2006) 1.67
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
Intracellular and extracellular ATP coordinately regulate the inverse correlation between osteoclast survival and bone resorption. J Biol Chem (2012) 1.66
Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat. Cell (2012) 1.65
Phosphatidylinositol-3-kinase-gamma is integral to homing functions of progenitor cells. Circ Res (2008) 1.65
DREAM is a critical transcriptional repressor for pain modulation. Cell (2002) 1.63
Complete cardiac regeneration in a mouse model of myocardial infarction. Aging (Albany NY) (2012) 1.60
Dissociating the dual roles of apoptosis-inducing factor in maintaining mitochondrial structure and apoptosis. EMBO J (2006) 1.59
Muscle-specific loss of apoptosis-inducing factor leads to mitochondrial dysfunction, skeletal muscle atrophy, and dilated cardiomyopathy. Mol Cell Biol (2005) 1.58
The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. Nat Med (2007) 1.55
Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol (2007) 1.55
Angiotensin-converting enzyme 2 attenuates oxidative stress and VSMC proliferation via the JAK2/STAT3/SOCS3 and profilin-1/MAPK signaling pathways. Regul Pept (2013) 1.54
Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. J Clin Invest (2010) 1.54
Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension (2009) 1.52
Blockage by SP600125 of Fcepsilon receptor-induced degranulation and cytokine gene expression in mast cells is mediated through inhibition of phosphatidylinositol 3-kinase signalling pathway. J Biochem (2008) 1.52
MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence. Nat Cell Biol (2004) 1.51
Essential role of Fkbp6 in male fertility and homologous chromosome pairing in meiosis. Science (2003) 1.51
Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J Exp Med (2003) 1.46
Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension (2010) 1.45
Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. J Mol Med (Berl) (2014) 1.45
Central control of fever and female body temperature by RANKL/RANK. Nature (2009) 1.42
Preferential signaling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells. J Exp Med (2003) 1.42
Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance. J Biol Chem (2011) 1.42
CLP1 links tRNA metabolism to progressive motor-neuron loss. Nature (2013) 1.41
Mitochondria, AIF and caspases--rivaling for cell death execution. Nat Cell Biol (2003) 1.40
Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res (2007) 1.40
The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat Med (2005) 1.39
Osteocyte control of osteoclastogenesis. Bone (2012) 1.36
Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. Circulation (2003) 1.36
Spinophilin regulates Ca2+ signalling by binding the N-terminal domain of RGS2 and the third intracellular loop of G-protein-coupled receptors. Nat Cell Biol (2005) 1.36
Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol (2006) 1.35
The molecular adapter Carma1 controls entry of IkappaB kinase into the central immune synapse. J Exp Med (2004) 1.35
Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc Natl Acad Sci U S A (2010) 1.34
RANKL/RANK-beyond bones. J Mol Med (Berl) (2011) 1.34
Leukocyte PI3Kgamma and PI3Kdelta have temporally distinct roles for leukocyte recruitment in vivo. Blood (2007) 1.33
Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol (2008) 1.32
AIF: not just an apoptosis-inducing factor. Ann N Y Acad Sci (2009) 1.31
p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity (2007) 1.30
T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b. Mol Cell Biol (2008) 1.30
Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail (2009) 1.29